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Abstract: Background: Whether long-term suppression of replica-
tion of hepatitis B virus (HBV) has any beneﬁcial effect on regression
of advanced liver ﬁbrosis associated with chronic HBV infection
remains unclear. We aimed to assess the effects on ﬁbrosis and
cirrhosis of at least 5 years’ treatment with tenofovir disoproxil
fumarate (DF) in chronic HBV infection.
Methods: After 48 weeks of randomised double-blind comparison
(trials NCT00117676 and NCT00116805) of tenofovir DF with adefo-
vir dipivoxil, participants (positive or negative for HBeAg) were eligi-
ble to enter a 7-year study of open-label tenofovir DF treatment,
with a pre-speciﬁed repeat liver biopsy at week 240. We assessed
histological improvement (P2 point reduction in Knodell necroin-
ﬂammatory score with no worsening of ﬁbrosis) and regression of
ﬁbrosis (P1 unit decrease by Ishak scoring system).
Findings: Of 641 patients who received randomised treatment, 585
(91%) entered the open-label phase, and 489 (76%) completed
240 weeks. 348 patients (54%) had biopsy results at both baseline
and week 240. 304 (87%) of the 348 had histological improvement,
and 176 (51%) had regression of ﬁbrosis at week 240 (p <00001).
Of the 96 (28%) patients with cirrhosis (Ishak score 5 or 6) at
baseline, 71 (74%) no longer had cirrhosis (P1 unit decrease in
score), whereas three of 252 patients without cirrhosis at base-
line progressed to cirrhosis at year 5 (p <00001). Virological
breakthrough occurred infrequently and was not due to resis-
tance to tenofovir DF. The safety proﬁle was favourable: 91
(16%) patients had adverse events but only nine patients had
serious events related to the study drug.
Interpretation: In patients with chronic HBV infection, up to
5 years of treatment with tenofovir DF was safe and effective.Journal of Hepatology 20
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Chronic hepatitis B virus (HBV) infection is a dynamic state of
interactions among HBV, hepatocytes, and host immune system.
The resultant hepatic necroinﬂammatory response to injury,
reﬂected by alanine aminotransferase (ALT) elevation or hepatitis
activity, during the immune clearance phase may stimulate new
ﬁbrogenesis that may even progress to advanced ﬁbrosis or cir-
rhosis [1].
It has been demonstrated, in a literature review of 26 prospec-
tive studies in 1996–2002, that there are signiﬁcant and
consistent correlations between HBV DNA level and necroinﬂam-
matory activity in both untreated patients and treated patients,
especially those with nucleos(t)ide analog (Nuc) therapy [2].
Since hepatic necroinﬂammatory activity is the main stimulator
of hepatic ﬁbrosis [1], it is conceivable that the ﬁbrogenetic pro-
cess will be arrested or even degraded along with the subsidence
of hepatitis activity subsequent to HBV suppression. Studies do
show that ﬁbrosis regressed >1 unit in a variable proportion of
patients after 1-year Nuc therapy [1]. Several studies have shown
that continued antiviral therapy is associated with continued
improvement in liver histology. More importantly, these studies
suggest that maintained HBV suppression is associated with
regression of advanced ﬁbrosis and even reversal of liver cirrhosis
[3–8]. However, these studies involved a small proportion of
patients enrolled in the original trials, and consisted of a small
number of patients and even a smaller number of patients with
advanced ﬁbrosis or cirrhosis (Table 1). In addition, there
were concerns about drug resistance and bias due to self-
selection of patients to undergo repeat biopsy [3]. Obviously,
the evidence from these earlier studies was not strong enough
to convincingly support a paradigm shift from the deep rooted
traditional concept to a new concept that cirrhosis is reversible.
The study of Marcellin et al. [9] on the long-term tenofovir
(TDF) therapy in a large number of patients, including patients
with advanced ﬁbrosis or cirrhosis, with prescheduled serial fol-
low-up biopsies comes timely to address these concerns. Among
the 641 patients enrolled in the original phase III trials, this study
included 344 patients with liver biopsy at baseline, year 1 and 5
of therapy. At baseline, 133 (38.7% of the 344 patients) had Ishak
ﬁbrosis scoresP4, including 96 (28% of 344) with cirrhosis (Ishak
ﬁbrosis score P5). Along with maintained HBV suppression in
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Table 1. Regression of ﬁbrosis in patients with advanced ﬁbrosis or cirrhosis
under nucleos(t)ide analog therapy.
Ref. No. of 
patients
HBeAg 
status
Fibrosis regression >1 
(%)
Fibrosis 
score
yr 1 3 4 ≥5
LAM [3] 30a + - 67a - - K
11b 73b
[4] 24a - 46a K
6b 50b
[6] 47a + 49a - - - I
57a - 53a - - -
ADV [5] 12a - 58a,c I
4b 75b,d
ETV [6] 46a + 57a I
51a - 59a
[7] 13a + or - - 85a - - K
[8] 10a + or - 40a - - 100a I
4b 0b 100b
TDF [9] 133a + or - 27a - - 68a I
96b - - - 74b
ADV, adefovir; ETV, entecavir; HBeAg, hepatitis B e antigen; K, Knodell; LAM,
lamivudine; Ref, reference; TDF, tenofovir; yr, year.
aPatients with advanced ﬁbrosis or cirrhosis.
bPatients with cirrhosis.
cIshak ﬁbrosis score (I) decreased >2 points.
dIshak ﬁbrosis improved by 4 points.
JOURNAL OF HEPATOLOGY99% of the patients and no or mild necroinﬂammation (Knodell
score 0–3) in 80% of the patients, Ishak ﬁbrosis scores improved
to <4 in 36 (27%) and 91 (68%) of the 133 patients at year 1
and 5, respectively. More importantly, 71 (74%) of the 96 patients
with liver cirrhosis at baseline had a reduction in ﬁbrosis >2 units
(except 1 patient) and were no longer cirrhotic at year 5.
Excluding patients with body-mass index (BMI) P25 kg/m2,
which was found to be a signiﬁcant negative predictor of cirrho-
sis regression, 29 (90%) of 32 patients with normal BMI were no
longer cirrhotic. Furthermore, only 7 (7.3%) of the 96 patients
with baseline cirrhosis developed hepatocellular carcinoma
(HCC) between week 50 and 206 of therapy. Though there were
no parallel untreated controls for comparison, the estimated
annual incidence is far lower than the previously reported annual
incidence of 2–6% in untreated cirrhotic patients. The results of
this prescheduled large and long-term histologic study in TDF
treated patients with advanced ﬁbrosis or cirrhosis have con-
ﬁrmed the preliminary observations in earlier small studies that
ﬁbrosis regression increases with the duration of maintained HBV
suppression. With similar potency and a low rate of drug resis-
tance, it is not clear why TDF treated patients with advanced
ﬁbrosis or cirrhosis tend to have numerically lower rates of ﬁbro-
sis regression than in entecavir treated counterparts [6–9]. Given
the big difference in the number of patients, perhaps the resultsJournal of Hepatology 201of the largest study is more accurate (Table 1). The interobserber
variation between different pathologists may also be a factor.
While the evidence for ﬁbrosis regression in this study is
pretty convincing, one may remain skeptical as to whether the
distorted liver parenchyma and altered blood ﬂow in the cirrhotic
liver are reversible. One study demonstrated that 12-month lam-
ivudine therapy reduced hepatic venous pressure gradient
(HVPG) in 18 of 19 patients with cirrhosis or decreased P20%
and <12 mmHg in 10 of 13 patients with baseline HVPG
P12 mmHg, suggesting that vascular changes of cirrhosis are
reversible in patients with virological and biochemical response
[10]. Together with the translated clinical beneﬁt of a far lower
incidence of HCC development in the study of Marcellin et al.
[9], there is little doubt that liver cirrhosis is reversible in Nuc
treated hepatitis B patients with maintained or sustained HBV
suppression and resolved hepatitis activity.Conﬂict of interest
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